Buccal Absorption of Biopharmaceutics Classification System III Drugs: Formulation Approaches and Mechanistic Insights
Pharmaceutics · 06.12.2024 · 16 (12) · 1563
DOI: 10.3390/pharmaceutics16121563 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 06.12.2024. Verfasst von Rayan Sabra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Aston Pharmacy School, Aston University, Birmingham B4 7ET, UK. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK, INNOVATE UK—KTP award.
Abstract (Originalsprache)
Buccal drug delivery emerges as a promising strategy to enhance the absorption of drugs classified under the Biopharmaceutics Classification System (BCS) Class III, characterized by high solubility and low permeability. However, addressing the absorption challenges of BCS Class III drugs necessitates innovative formulation strategies. This review delves into optimizing buccal drug delivery for BCS III drugs, focusing on various formulation approaches to improve absorption. Strategies such as permeation enhancers, mucoadhesive polymers, pH modifiers, ion pairing, and prodrugs are systematically explored for their potential to overcome challenges associated with BCS Class III drugs. The mechanistic insight into how these strategies influence drug absorption is discussed, providing a detailed understanding of their applicability. Furthermore, the review advocates for integrating conventional buccal dosage forms with these formulation approaches as a potential strategy to enhance absorption. By emphasizing bioavailability enhancement, this review contributes to a holistic understanding of optimizing buccal absorption for BCS Class III drugs, presenting a unified approach to overcome inherent limitations in their delivery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aston Pharmacy School, Aston University, Birmingham B4 7ET, UK.
- Catalent Pharma Solutions U.K. Swindon Zydis® Limited, Swindon SN5 8RU, UK.
ORCID-Profile: Daniel Kirby
Förderung
- Innovate UK
- INNOVATE UK—KTP award
Zitieren
APA
Sabra, R., Kirby, D., Chouk, V., Malgorzata, K., & Mohammed, A. R. (2024). Buccal Absorption of Biopharmaceutics Classification System III Drugs: Formulation Approaches and Mechanistic Insights. Pharmaceutics, 16(12), 1563. https://doi.org/10.3390/pharmaceutics16121563
Vancouver
Sabra R, Kirby D, Chouk V, Malgorzata K, Mohammed AR. Buccal Absorption of Biopharmaceutics Classification System III Drugs: Formulation Approaches and Mechanistic Insights. Pharmaceutics. 2024;16(12):1563. doi:10.3390/pharmaceutics16121563
BibTeX
@article{Sabra2024,
author = {Sabra, Rayan and Kirby, Daniel and Chouk, Vikram and Malgorzata, Kleta and Mohammed, Afzal R},
title = {Buccal Absorption of Biopharmaceutics Classification System III Drugs: Formulation Approaches and Mechanistic Insights},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {12},
pages = {1563},
doi = {10.3390/pharmaceutics16121563}
}
EUVIMED